Time for Reeves to recognise reality: AstraZeneca has killed stamp duty on shares | Nils Pratley
PositiveFinancial Markets

AstraZeneca's recent proposal to list its shares directly on the New York Stock Exchange while maintaining its presence in London and Stockholm has sparked a significant discussion about the current tax structure affecting shareholders. This move highlights the need for tax reforms that could benefit investors and enhance market competitiveness. By addressing these flaws, AstraZeneca not only aims to streamline its operations but also sets a precedent for other companies considering similar paths, making it a pivotal moment in the financial landscape.
— Curated by the World Pulse Now AI Editorial System










